Holen Sie sich die Stockscreener-App
38.51
1.13%
-0.44
Handel nachbörslich:
38.63
0.12
+0.31%
Schlusskurs vom Vortag:
$38.95
Offen:
$38.51
24-Stunden-Volumen:
4.88M
Relative Volume:
0.93
Marktkapitalisierung:
$84.30B
Einnahmen:
$40.23B
Nettoeinkommen (Verlust:
$3.98B
KGV:
19.97
EPS:
1.9285
Netto-Cashflow:
$4.94B
1W Leistung:
+0.60%
1M Leistung:
-7.56%
6M Leistung:
+13.43%
1J Leistung:
+0.79%
1-Tages-Spanne:
$38.28
$38.87
1-Wochen-Bereich:
$38.22
$39.40
52-Wochen-Spanne:
$31.71
$44.67
Gsk Plc Adr Stock (GSK) Company Profile
Vergleichen Sie GSK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
38.51 | 84.30B | 40.23B | 3.98B | 4.94B | 1.9285 |
|
LLY
Lilly Eli Co
|
779.28 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.56 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.82 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
190.75 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
123.81 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
Validea Detailed Fundamental AnalysisGSK - Nasdaq
The 10 Best Companies to Invest in Now - Morningstar
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data - Benzinga
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
The Best Healthcare Stocks to Buy - Morningstar
FDA Approves GSK's Nucala for Expanded Use in COPD - Yahoo Finance
Why Value Investing Has Worked Better Outside the US - Morningstar
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance
Ratios in Focus: Analyzing GSK Plc ADR (GSK)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
There Is A Lot Of Upside Potential For GSK Plc ADR(NYSE: GSK) - Stocksregister
Here's Why GSK (GSK) is a Strong Growth Stock - Nasdaq
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance - TradingView
GSK Plc ADR [GSK] gain 15.23% so far this year. What now? - dbtnews.com
GSK’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
GSK to Report First-Quarter Earnings: Is a Beat in Store? - Nasdaq
An analyst sees good growth prospects for GSK Plc ADR (GSK) - Sete News
GSK Plc ADR [GSK] Investment Guide: What You Need to Know - knoxdaily.com
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
GSK’s Market Whiplash: 8.94% YTD Rise, -6.10% Plunge in 30 Days - investchronicle.com
GSK Securities Class Action: GSK PLC Investors Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the GSK Class Action Lawsuit - Finansavisen
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP - TradingView
Best International Companies to Own: 2025 Edition - Morningstar
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money - GlobeNewswire
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming DeadlinesGSK - Finansavisen
Is GSK plc (GSK) the Best ADR Stock to Buy According to Hedge Funds? - Insider Monkey
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology - Morningstar
GSK FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection - Yahoo Finance
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit - PR Newswire
Best international companies to own: 2023 Edition - Morningstar
How Do Things Look For GSK Plc ADR (NYSE: GSK) In The Short-Term? - Stocks Register
GSK Lead Plaintiff Deadline Approaching – Contact Robbins - GlobeNewswire
GSK Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action - TradingView
Why GSK (GSK) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):